Use of hormone therapies in disseminated carcinomatosis of the bone marrow associated with hormone receptor-positive breast cancer

被引:3
作者
Ota, Takayo [1 ]
Miyatake, Nozomi [1 ]
Tanaka, Noriko [2 ]
Hasegawa, Yoshikazu [1 ]
Tokunaga, Masahiro [2 ]
Tsukuda, Hiroshi [1 ]
Fukuoka, Masahiro [1 ]
机构
[1] Izumi Municipal Hosp, Dept Med Oncol, 4-10-10 Fuchu, Izumi, Osaka 5940071, Japan
[2] Izumi Municipal Hosp, Dept Radiol, Izumi, Osaka, Japan
关键词
Breast cancer; disseminated carcinomatosis of the bone marrow; hormone therapy; zoledronic acid; GASTRIC-CANCER; METASTASIS; PROGNOSIS;
D O I
10.1080/09513590.2017.1393063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disseminated carcinomatosis of the bone marrow (DCBM) is diffusely invasive bone metastasis resulting from solid tumors. DCBM is often associated with disseminated intravascular coagulation (DIC) or hemolytic anemia. Generally, DCBM treatment includes cytotoxic chemotherapy for underlying solid tumors and management of hematological conditions if present. We report a case of DCBM accompanied with DIC in hormone receptor-positive breast cancer. Due to her life-threatening condition, we used hormone therapies, not cytotoxic chemotherapies, to treat her DCBM. With zoledronic acid, her DIC and general condition gradually improved and eventually she could return to her daily life. If DCBM occurs in hormone receptor-positive breast cancer, hormone therapy can be one of the treatment choices.
引用
收藏
页码:286 / 289
页数:4
相关论文
共 50 条
[1]   Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer [J].
Freelander, Allegra ;
Brown, Lauren J. ;
Parker, Andrew ;
Segara, Davendra ;
Portman, Neil ;
Lau, Brandon ;
Lim, Elgene .
GENES, 2021, 12 (02) :1-24
[2]   Disparities in Hormone Receptor-Positive Breast Cancer [J].
Ogayo, Esther R. ;
Mittendorf, Elizabeth A. ;
Kantor, Olga .
CURRENT BREAST CANCER REPORTS, 2024, 16 (01) :106-115
[3]   Disparities in Hormone Receptor-Positive Breast Cancer [J].
Esther R. Ogayo ;
Elizabeth A. Mittendorf ;
Olga Kantor .
Current Breast Cancer Reports, 2024, 16 :106-115
[4]   Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer [J].
Almstedt, Katrin ;
Schmidt, Marcus .
BREAST CARE, 2015, 10 (03) :168-172
[5]   Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer [J].
Sehdev, S. ;
Martin, G. ;
Sideris, L. ;
Lam, W. ;
Brisson, S. .
CURRENT ONCOLOGY, 2009, 16 :S16-S25
[6]   The challenges of modeling hormone receptor-positive breast cancer in mice [J].
Ozdemir, Berna C. ;
Sflomos, George ;
Brisken, Cathrin .
ENDOCRINE-RELATED CANCER, 2018, 25 (05) :R319-R330
[7]   Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer [J].
Sparano, Joseph A. ;
Wang, Molin ;
Zhao, Fengmin ;
Stearns, Vered ;
Martino, Silvana ;
Ligibel, Jennifer A. ;
Perez, Edith A. ;
Saphner, Tom ;
Wolff, Antonio C. ;
Sledge, George W., Jr. ;
Wood, William C. ;
Fetting, John ;
Davidson, Nancy E. .
CANCER, 2012, 118 (23) :5937-5946
[8]   Cannabinoids and Hormone Receptor-Positive Breast Cancer Treatment [J].
Dobovisek, Luka ;
Krstanovic, Fran ;
Borstnar, Simona ;
Debeljak, Natasa .
CANCERS, 2020, 12 (03)
[9]   Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer [J].
Beomyoung Cho ;
Maria Pérez ;
Donna B. Jeffe ;
Matthew W. Kreuter ;
Julie A. Margenthaler ;
Graham A. Colditz ;
Ying Liu .
BMC Cancer, 22
[10]   Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer [J].
Cho, Beomyoung ;
Perez, Maria ;
Jeffe, Donna B. ;
Kreuter, Matthew W. ;
Margenthaler, Julie A. ;
Colditz, Graham A. ;
Liu, Ying .
BMC CANCER, 2022, 22 (01)